CA2507186A1 - Anilinopyrazole derivatives useful for the treatment of diabetes - Google Patents

Anilinopyrazole derivatives useful for the treatment of diabetes Download PDF

Info

Publication number
CA2507186A1
CA2507186A1 CA002507186A CA2507186A CA2507186A1 CA 2507186 A1 CA2507186 A1 CA 2507186A1 CA 002507186 A CA002507186 A CA 002507186A CA 2507186 A CA2507186 A CA 2507186A CA 2507186 A1 CA2507186 A1 CA 2507186A1
Authority
CA
Canada
Prior art keywords
optionally substituted
alkoxy
pyrazol
amino
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002507186A
Other languages
English (en)
French (fr)
Inventor
Joachim Rudolph
Louis-David Cantin
Steven Magnuson
William Bullock
Ann-Marie Bullion
Libing Chen
Chih-Yuan Chuang
Sidney Liang
Dyuti Majumdar
Herbert Ogutu
Alan Olague
Ning Qi
Philip L. Wickens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharmaceuticals Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2507186A1 publication Critical patent/CA2507186A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA002507186A 2002-11-27 2003-11-25 Anilinopyrazole derivatives useful for the treatment of diabetes Abandoned CA2507186A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US42991702P 2002-11-27 2002-11-27
US60/429,917 2002-11-27
US49821403P 2003-08-27 2003-08-27
US60/498,214 2003-08-27
PCT/US2003/037829 WO2004050651A1 (en) 2002-11-27 2003-11-25 Anilinopyrazole derivatives useful for the treatment of diabetes

Publications (1)

Publication Number Publication Date
CA2507186A1 true CA2507186A1 (en) 2004-06-17

Family

ID=32474531

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002507186A Abandoned CA2507186A1 (en) 2002-11-27 2003-11-25 Anilinopyrazole derivatives useful for the treatment of diabetes

Country Status (16)

Country Link
US (2) US7265144B2 (cg-RX-API-DMAC7.html)
EP (1) EP1567517A1 (cg-RX-API-DMAC7.html)
JP (1) JP2006510728A (cg-RX-API-DMAC7.html)
KR (1) KR20050085170A (cg-RX-API-DMAC7.html)
AR (1) AR042067A1 (cg-RX-API-DMAC7.html)
AU (2) AU2003295890A1 (cg-RX-API-DMAC7.html)
BR (1) BR0316723A (cg-RX-API-DMAC7.html)
CA (1) CA2507186A1 (cg-RX-API-DMAC7.html)
HN (1) HN2003000379A (cg-RX-API-DMAC7.html)
MX (1) MXPA05004621A (cg-RX-API-DMAC7.html)
MY (1) MY141528A (cg-RX-API-DMAC7.html)
PE (1) PE20040907A1 (cg-RX-API-DMAC7.html)
PL (1) PL377164A1 (cg-RX-API-DMAC7.html)
TW (1) TW200418803A (cg-RX-API-DMAC7.html)
UY (1) UY28098A1 (cg-RX-API-DMAC7.html)
WO (2) WO2004050650A1 (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2567352A1 (en) * 2004-05-20 2005-12-01 Bayer Pharmaceuticals Corporation 5-anilino-4-heteroarylpyrazole derivatives useful for the treatment of diabetes
EP1860098B1 (en) 2005-03-16 2012-11-14 Toyama Chemical Co., Ltd. Novel anthranilic acid derivative or salt thereof
ES2400371T3 (es) * 2005-07-07 2013-04-09 Abbott Laboratories Promotores de la apoptosis
CA2620425A1 (en) * 2005-08-31 2007-03-08 Bayer Healthcare Llc Anilinopyrazole derivatives useful for the treatment of diabetes
WO2007129195A2 (en) * 2006-05-04 2007-11-15 Pfizer Products Inc. 4-pyrimidine-5-amino-pyrazole compounds
ATE550326T1 (de) * 2006-07-31 2012-04-15 Cadila Healthcare Ltd Als modulatoren von hdl einsetzbare verbindungen
AU2007305016B2 (en) 2006-10-02 2011-11-03 Novartis Ag Compounds and compositions as protein kinase inhibitors
WO2008093639A1 (ja) 2007-01-29 2008-08-07 Takeda Pharmaceutical Company Limited ピラゾール化合物
CA2698928A1 (en) * 2007-09-28 2009-04-09 Absolute Science, Inc. Compounds and methods for treating zinc matrix metalloprotease dependent diseases
DE102008039083A1 (de) 2008-08-21 2010-02-25 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Aminopyrazole und ihre Verwendung
DE102008039082A1 (de) 2008-08-21 2010-02-25 Bayer Schering Pharma Aktiengesellschaft Azabicyclisch-substituierte 5-Aminopyrazole und ihre Verwendung
WO2010033360A1 (en) * 2008-09-19 2010-03-25 1/3 Absolute Science, Inc. Methods of treating a botulinum toxin related condition in a subject
MX2011002793A (es) 2008-09-25 2011-04-05 Hoffmann La Roche Derivados de 3-amino-indazol o de 3-amino-4,5,6,7-tetrahidro-indaz ol.
AR075713A1 (es) 2009-03-03 2011-04-20 Du Pont Pirazoles fungicidas
TWI504350B (zh) * 2010-09-01 2015-10-21 Du Pont 殺真菌吡唑及其混合物
TWI568721B (zh) 2012-02-01 2017-02-01 杜邦股份有限公司 殺真菌之吡唑混合物
US9630976B2 (en) 2012-07-03 2017-04-25 Ono Pharmaceutical Co., Ltd. Compound having agonistic activity on somatostatin receptor, and use thereof for medical purposes
CN103074693A (zh) * 2013-01-18 2013-05-01 桐昆集团股份有限公司 带双导丝辊的poy纺丝卷绕装置
CA2972013C (en) 2013-12-23 2020-04-28 Amazentis Sa Process-scale synthesis of urolithins
EP3805213A3 (en) 2015-06-18 2021-06-09 Nippon Soda Co., Ltd. 1-(2-(ethylsulfonyl)-phenyl)-4-(phenyl)-1h-1,2,3-triazole and 4-(2-(ethylsulfonyl)-phenyl)-1-(phenyl)-1h-1,2,3-triazole and related compounds derivatives as pesticides
KR102420892B1 (ko) * 2017-05-26 2022-07-14 쟝쑤 애텀 바이오사이언스 앤드 파머수티컬 컴퍼니 리미티드 요산 배출을 촉진시키는 urat1 억제제
WO2020227368A1 (en) * 2019-05-08 2020-11-12 Trustees Of Boston University Hsp90 inhibitors and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL134200C (cg-RX-API-DMAC7.html) 1960-04-14
US3790576A (en) 1972-03-20 1974-02-05 Parke Davis & Co 9 substituted 4,9-dihydro-1,3,4,4-tetraalkyl-1h-pyrazolo(3,4-b)quinolines
HUT69739A (en) 1992-03-26 1995-09-28 Dowelanco Process for producing n-heterocyclic nitroanilines and fungicides containing the compounds
CA2203517A1 (en) 1994-11-10 1996-05-23 Alan M. Laibelman Pharmaceutical pyrazole compositions useful as inhibitors of protein kinases
DE19532066A1 (de) 1995-08-31 1997-03-06 Bayer Ag Substituierte 5-Aminopyrazole
FR2763334A1 (fr) * 1997-05-13 1998-11-20 Lipha Derives anthraniliques
US5998424A (en) 1997-06-19 1999-12-07 Dupont Pharmaceuticals Company Inhibitors of factor Xa with a neutral P1 specificity group
US5942520A (en) 1998-01-27 1999-08-24 Cell Pathways, Inc. Method for inhibiting neoplastic cells by exposure to substituted N-cycloalkylmethyl-1-H-pyrazolo (3,4-B) quinolone-4 amines
EP1597234B1 (en) * 2003-02-27 2008-10-08 Smithkline Beecham Corporation Novel compounds

Also Published As

Publication number Publication date
US7265144B2 (en) 2007-09-04
HN2003000379A (es) 2005-12-20
AU2003297565A1 (en) 2004-06-23
UY28098A1 (es) 2004-06-30
AU2003295890A1 (en) 2004-06-23
US20040157904A1 (en) 2004-08-12
US20080064734A1 (en) 2008-03-13
KR20050085170A (ko) 2005-08-29
TW200418803A (en) 2004-10-01
WO2004050651A1 (en) 2004-06-17
PE20040907A1 (es) 2005-01-27
EP1567517A1 (en) 2005-08-31
MY141528A (en) 2010-05-14
PL377164A1 (pl) 2006-01-23
WO2004050650A1 (en) 2004-06-17
BR0316723A (pt) 2005-10-18
AR042067A1 (es) 2005-06-08
JP2006510728A (ja) 2006-03-30
MXPA05004621A (es) 2005-06-08
HK1087103A1 (zh) 2006-10-06

Similar Documents

Publication Publication Date Title
US20080064734A1 (en) Anilinopyrazole derivatives useful for the treatment of diabetes
JP5767631B2 (ja) バニロイド受容体リガンドとしての置換された芳香族カルボキサミドおよび尿素誘導体
JP6948322B2 (ja) Apj受容体のapjアゴニストとしてのヘテロアリールヒドロキシピリミジノン
US20090209451A1 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
JP2013545740A (ja) バニロイド受容体リガンドとしての置換された複素芳香族カルボキサミド誘導体および尿素誘導体
US10954232B2 (en) Pyrazole derivative as ALK5 inhibitor and uses thereof
CN101679279B (zh) 作为5-ht6拮抗剂的磺酰吡唑啉甲脒衍生物
JP7492597B2 (ja) Gpr52モジュレーター化合物
PT1024138E (pt) Derivados de pirazole
JP2013534229A (ja) バニロイド受容体リガンドとしての置換された環状カルボキサミド誘導体および尿素誘導体
AU2010328049A1 (en) Azocyclic inhibitors of fatty acid amide hydrolase
JP2013253019A (ja) 新規なピペリジン誘導体及びこれを含有する医薬
CA2743489A1 (en) Substituted bicyclic amines for the treatment of diabetes
TW200533656A (en) Therapeutic agents
EP1928455A1 (en) Anilinopyrazole derivatives useful for the treatment of diabetes
JP2019001715A (ja) 三環性化合物
JP2020524660A (ja) Ror−ガンマモジュレーターとして有用な2,3−ジヒドロイソインドール−1−カルボキサミド
US11597702B2 (en) Substituted pyrazoles FFA4/GPR120 receptor agonists
US20080009531A1 (en) 5-Anilino-4-Heteroarylpyrazole Derivatives Useful for the Treatment of Diabetes
HK1087103B (en) Anilinopyrazole derivatives useful for the treatment of diabetes
JP2013542231A (ja) バニロイド受容体リガンドとしての置換された二環式芳香族カルボキサミド誘導体および尿素誘導体
ZA200505055B (en) Anilinopyrazole derivatives useful for the treatment of diabetes
WO2019188456A1 (ja) 新規抗腫瘍剤
MXPA06008833A (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
TW200916442A (en) 4, 5-dihydro-(1H)-pyrazole derivatives as cannabinoid CB1receptor modulators

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued